Innate Pharma S.A. ADS(IPHA)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

IPHA iron condor setups IPHA expected move IPHA IV rank history IPHA Fibonacci levels IPHA insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

IPHA — —
Snapshot
Info
Exchange
XNAS
Market Cap
$0.2B

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaborat…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -5.20% 6
Feb -4.41% 6
Mar -4.46% 6
Apr -3.14% 6
May +5.48% 6
Jun -7.88% 6
Jul +2.95% 6
Aug +4.81% 6
Sep -8.75% 6
Oct +3.10% 5
Nov -1.94% 5
Dec +19.24% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.95
SMA 50: $1.97
SMA 200: $1.75
Current: $1.70
EMA 12: $1.84
EMA 26: $1.93
MACD: -0.0823 | Signal: -0.0331
BEARISH
ADX (14): 13.67
RANGE
+DI: 21.98
−DI: 29.41

Momentum Oscillators

RSI (14): 34.98
NEUTRAL
Stoch %K: 5.73
Stoch %D: 5.35
Williams %R: -84.76

Volume & Volatility

BB Upper: $2.26
BB Lower: $1.64
NEUTRAL
OBV: 55,403,292
Vol SMA 20: 45,652
Vol ROC: 272.63%
ATR: $0.12
True Range: $0.09
HV 20: 44.7%
HV 30: 70.4%
HV 60: 83.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-25T00:00:00 – 2026-09-25T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: IPHA

Executive Summary: Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Bullish momentum signals from MACD and RSI
  • Recent positive news headlines on cancer drug pipeline acceleration
  • High volatility, indicating potential for significant price movements

Primary Risks:

  • Overbought conditions on RSI and Bollinger Bands
  • Strong negative sentiment from recent news headline about a third cancer drug entering the clinic at an under-$20-million company

Investment Thesis: IPHA's strong technical momentum signals, driven by its cancer drug pipeline acceleration, may lead to short-term upside. However, the stock is overbought and subject to volatility. Investors should consider risk management strategies and monitor for potential pullbacks.

Recent News Sentiment Impact: The positive news headlines on cancer drug pipeline acceleration have contributed to IPHA's recent price appreciation. The neutral sentiment from the third cancer drug entering the clinic has not significantly impacted the stock's momentum.

Technical Analysis:

Trend Direction:

  • Short-term: Uptrend
  • Medium-term: Range-bound
  • Long-term: Bullish

Support/Resistance Levels:

  • Resistance 1: $2.22 (current price)
  • Resistance 2: $2.43 (upper Bollinger Band)
  • Support 1: $1.79 (SMA 20)

Momentum Signals:

  • RSI Interpretation: Overbought (>70)
  • MACD Signal: Bullish momentum
  • Bollinger Bands Position: Squeeze

Volume Analysis:

Volume trends indicate increasing institutional interest and volatility.

News & Sentiment Analysis:

Recent Headlines Summary:

Positive news headlines on cancer drug pipeline acceleration have driven IPHA's recent price appreciation. Neutral sentiment from a third cancer drug entering the clinic has not significantly impacted the stock's momentum.

Sentiment Assessment:

Sentiment is NEUTRAL, reflecting mixed market commentary and routine announcements.

Catalyst Identification:

Earnings dates, FDA approvals, product launches, and regulatory changes may impact IPHA's price movement.

Risk & Volatility Assessment:

Beta Interpretation:

Beta of 1.48 indicates high risk relative to the broader market (SPY).

Volatility Regime:

High volatility (>0.95) suggests potential for significant price movements.

Options Market Signals:

No options data available, making it difficult to assess market sentiment and position sizing considerations.

Market Context & Positioning:

Sector Performance:

Relative strength vs sector/market is NEUTRAL.

Institutional Activity:

Institutional interest signals increased participation in IPHA's recent price appreciation.

Correlation Analysis:

Correlation with the broader market (SPY) is LOW (0.20).

Key Levels & Action Items:

Critical Price Levels:

Support 1: $1.79 (SMA 20) Resistance 1: $2.22 (current price)

Breakout/Breakdown Levels:

None identified based on technical analysis

Time-Sensitive Catalysts:

Earnings dates, FDA approvals, product launches, and regulatory changes may impact IPHA's price movement.

Risk Management: Consider stop-loss levels and position sizing considerations to manage risk exposure. Monitor for potential pullbacks and consider adjusting the portfolio accordingly.

Generated
News
Options Activity
Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.53
Correlation (SPY)
20.1%
R²
0.04
Ann. Volatility
99.2%
SPY Volatility
13.0%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

10 filers192,418 shares$354.05K value
# Filer Shares Value % of Total % of Float Period
1 Lion Point Capital, LP 81,151 $149.32K 42.17% — 2026-06-30
2 MORGAN STANLEY Custodian 43,524 $80.08K 22.62% — 2026-06-30
3 SmartHarvest Portfolios, LLC 23,750 $43.70K 12.34% — 2026-06-30
4 XTX Topco Ltd 15,130 $27.84K 7.86% — 2026-06-30
5 CITADEL ADVISORS LLC Custodian 12,441 $22.89K 6.47% — 2026-06-30
6 JANE STREET GROUP, LLC Custodian 10,310 $18.97K 5.36% — 2026-06-30
7 RHUMBLINE ADVISERS 4,719 $8.68K 2.45% — 2026-06-30
8 UBS Group AG Custodian 1,363 $2.51K 0.71% — 2026-06-30
9 Farther Finance Advisors, LLC Custodian 21 $38 0.01% — 2026-06-30
10 GAMMA Investing LLC 9 $17 <0.01% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.